High Risk Percutaneous Coronary Intervention Clinical Trial
— HM PHP CE MarkOfficial title:
HeartMate PHP™ CE Mark Clinical Investigation Plan
| NCT number | NCT02156609 |
| Other study ID # | PHPCEMark |
| Secondary ID | |
| Status | Completed |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | June 2014 |
| Est. completion date | December 2015 |
| Verified date | June 2022 |
| Source | Abbott Medical Devices |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The HeartMate PHP is a catheter-based pump designed to provide partial left heart circulatory support. The study will assess the safety and performance of the HeartMate PHP in supporting patients who are hemodynamically unstable, or at risk of being hemodynamically unstable, while undergoing percutaneous coronary interventions (PCI), such as coronary stent placement.
| Status | Completed |
| Enrollment | 50 |
| Est. completion date | December 2015 |
| Est. primary completion date | November 2015 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - At least 18 years of age. - Patient presents with a non-emergent need for complex PCI with: 1. an ejection fraction of =35% requiring hemodynamic support during the procedure, AND 2. the heart team has determined that the patient is not an optimal surgical candidate, OR the patient elects not to undergo surgery - Written, signed, and dated informed consent Exclusion Criteria: - Emergent PCI - ST elevation myocardial infarction within 7 days of procedure - Cardiac arrest within 7 days of procedure requiring CPR or defibrillation - Hemodynamic support with the HeartMate PHP post-PCI is anticipated - Cardiogenic shock (SBP <90 mmHg for >1 hour with either cool clammy skin OR oliguria OR altered sensorium OR cardiac index <2.2 L/min/m2) - Mural thrombus in the left ventricle - History of aortic valve replacement - Documented presence of aortic stenosis (orifice area of 1.5cm2 or less) - Moderate to severe aortic insufficiency (echocardiographic assessment of aortic insufficiency graded as 2 or higher) - Severe peripheral vascular disease - Abnormalities of the aorta that would preclude surgery, including aneurysms and significant tortuosity or calcifications - Planned use of rotablator or atherectomy during the procedure - Serum creatinine > 3.5mg/dL within 7 days of procedure - Liver dysfunction with elevation of liver enzymes and bilirubin levels to = 3x ULN or INR (Internationalized Normalized Ratio) =2 - Uncorrectable abnormal coagulation parameters - Active systemic infection requiring treatment with antibiotics - Clinically relevant stroke or TIA within 3 months of procedure. Patients with suspected stroke or TIA within 3 months of procedure must have documented absence of neurological infarction - Uncontrollable allergy or intolerance to heparin, aspirin, clopidogrel, ionic and nonionic contrast media, or any other potentially required anticoagulants or antiplatelet therapy drugs - History of heparin induced thrombocytopenia - Patient is pregnant or planning to become pregnant during the study period - Participation in another clinical study of an investigational drug or device that has not met its primary endpoint- |
| Country | Name | City | State |
|---|---|---|---|
| Colombia | Instituto del Corazon | Bucaramanga | |
| Netherlands | Erasmus Medical Center | Rotterdam | |
| Paraguay | Sanatorio Italiano | Asuncion | |
| Poland | Samodzielny Publiczny Szpital (The Prof. Leszka Gieca Upper-Silesian Medical Centre) | Katowice | |
| Poland | University Hospital in Krakow (John Paul II) | Krakow | |
| Poland | The Cardinal Stefan Wyszynski Institute of Cardiology | Warszawa | |
| Poland | Slaskie Centrum Chorob Serca w Zabrzu (Silesian Center for Heart Disease) | Zabrze |
| Lead Sponsor | Collaborator |
|---|---|
| Abbott Medical Devices |
Colombia, Netherlands, Paraguay, Poland,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Primary Endpoint | Primary Performance Endpoint: Freedom from hemodynamic compromise during PCI procedure defined as: Mean Arterial Pressure (MAP) not falling below 60mm Hg for more than 10 minutes during the PCI procedure and additional pressor medication is not required. Primary Endpoint will be evaluated at: Post procedure or at hospital discharge (whichever is longer) 30 days post procedure |
Post procedure or at hospital discharge (whichever is longer), 30 days post procedure | |
| Primary | Composite of Major Adverse Events (MAE) | Primary Safety Endpoint: Composite of Major Adverse Events (MAE): device-related cardiac death, new Q wave myocardial infarction, surgical intervention due to device complication or malfunction, device-related access site complication requiring intervention or device-related limb ischemia, cerebral vascular accident (CVA), new or worsening aortic valve insufficiency, major bleeding complication (BARC 3 or >), severe hypotension Primary Endpoint will be evaluated at: Post procedure or at hospital discharge (whichever is longer) 30 days post procedure |
Post procedure or at hospital discharge (whichever is longer), 30 days post procedure | |
| Secondary | Secondary Endpoint | Efficacy of hemodynamic support as measured by: Maximal decrease in cardiac power output (CPO) from baseline Changes in central venous pressure from baseline (CVP) Changes in pulmonary artery pressure from baseline (PAP) Changes in pulmonary capillary wedge pressure from baseline (PCWP) Changes in cardiac output from baseline (CO) Changes in cardiac index from baseline (CI) |
Post procedure or at hospital discharge (whichever is longer), 30 days post procedure | |
| Secondary | Major Adverse Event Composites | Individual components of the major adverse event composites | Post procedure or at hospital discharge (whichever is longer), 30 days post procedure |